26 March 2025 - There are significant uncertainties regarding long term efficacy and durability of sonpiretigene isteparvovec; ICER estimates that ...
6 February 2025 - Public comment period now open until 6 March 2025; requests to make oral comment during public ...
5 February 2025 - Current evidence suggests that suzetrigine may provide a net health benefit when compared to no systemic ...
12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported ...
31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; ...
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...
5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...
2 July 2024 - There are significant uncertainties regarding long term efficacy and safety of imetelstat; treatment would achieve common ...
30 May 2024 - Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds ...
26 March 2024 - Public comment period now open until 22 April 2024; requests to make oral comment during public ...
5 December 2023 - Public comment period now open until 9 January 2024; requests to make oral comment during public ...
28 November 2023 - Public comment period now open until 22 December 2023; requests to make oral comment during public meeting ...
14 November 2023 - Sotatercept added to background therapy appears to improve clinical outcomes, but there are uncertainties on long ...
30 October 2023 - Independent appraisal committee voted that across all patient sub-populations, arsa-cel demonstrated a net health benefit when ...
25 September 2023 - Registration now open for 5 October “Early Insights” webinar. ...